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ABSTRACT
Purpose: To examine the efficacy of adjuvant photoactivated chromophore for infectious 
keratitis–corneal cross-linking (PACK-CXL) for the treatment of infectious keratitis (IK).
Methods: Electronic databases, including MEDLINE, EMBASE and Cochrane Central, were 
searched for articles related to PACK-CXL. All clinical studies, including randomized 
controlled trials (RCTs), non-randomized controlled studies, case series and case reports, 
were included. A meta-analysis was further performed when there were sufficient similarities 
in the included RCTs. Primary outcome measure was time to complete corneal healing and 
secondary outcome measures included size of epithelial defect and infiltrate, corrected-
distance-visual-acuity (CDVA), and adverse events.
 
Results: Forty-six eligible studies (including four RCTs) with 435 patients were included. 
When compared to standard antimicrobial treatment (SAT) alone, adjuvant PACK-CXL 
resulted in shorter mean time to complete corneal healing (-7.44 days; 95% CI, -10.71 to -
4.16) and quicker resolution of the infiltrate at 7 days (-5.49mm2; 95% CI, -7.44 to -3.54) and 
at 14 to 30 days (-5.27mm2; 95% CI, -9.12 to -1.41). There was no significant difference in 
the size of epithelial defect, CDVA and risk of adverse events. Evidence on the use of 
PACK-CXL in acanthamoeba and mixed IK was insufficient.
Conclusions: Our study demonstrates that adjuvant PACK-CXL expedites the healing of IK 
when compared to SAT alone (low-quality evidence). Further adequately powered, high-
quality RCTs are required to fully ascertain the therapeutic effect of PACK-CXL.
Keywords: Antibiotic; Antimicrobial; Corneal infection; Corneal ulcer; Cross-linking; CXL; 
Microbial keratitis; Infectious keratitis; PACK-CXL
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INTRODUCTION
Infectious keratitis (IK) represents the leading cause for corneal blindness in the world.1, 2 It 
is a common, yet potentially sight-threatening, ophthalmic emergency that often warrants 
hospital admission for intensive antibiotic treatment and monitoring.3, 4 It can be caused by a 
wide array of microorganisms, including bacteria, fungi, viruses and parasites. Broad-
spectrum antimicrobial therapy is currently the mainstay of treatment for IK; however there is 
a decline in efficacy of antibiotic treatment due to an emerging trend of antimicrobial 
resistance in ocular infection.5-7 Furthermore complications such as corneal melt, perforation 
and endophthalmitis, may ensue despite timely and intensive topical antibiotic treatment, 
necessitating further surgical interventions such as tectonic or therapeutic keratoplasty in a 
trial to preserve the eye and vision.3, 4, 8, 9 However performing tectonic / therapeutic 
keratoplasty in a “hot eye” is associated with an increased incidence of recurrence of the 
disease, uncontrolled intraocular pressure, and graft rejection / failure.3, 10 These issues 
highlight the need for alternative or adjuvant antimicrobial treatment to supplement the 
current therapeutic armamentarium for IK.
Corneal cross-linking (CXL) was first introduced in 2003 by Wollensak et al.11 to stabilize the 
progression of keratoconus. It utilizes a combination of ultraviolet-A (UVA) light of 370 nm 
and photosensitizing agent “riboflavin” to increase the corneal biomechanical stability and 
rigidity. The long-term efficacy and safety of CXL for corneal ectatic disorders have been 
well established by many long-term studies.12-14 In addition to the stiffening effect on the 
cornea, CXL has been increasingly used for IK in the recent years. The rationale for using 
CXL for infection is based on the strong inherent antimicrobial activity of the UV light, which 
can directly damage the DNA and RNA of various types of microorganisms. Furthermore, 
the reactive oxygen species released from photoactivated riboflavin can directly affect the 
DNA and cell membranes of the microorganisms, culminating in a powerful synergistic 
antimicrobial action.15-17 These effects together with the increased corneal rigidity and hence 
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resistance to proteolytic enzymatic digestion of stromal collagen has made CXL an attractive 
adjuvant in the management of IK.18
In view of the emerging evidence of CXL for infectious keratitis, a new terminology – Photo-
Activated Chromophore for Keratitis – Corneal Cross-Linking (PACK-CXL) – was coined in 
2013 at the ninth CXL congress in Dublin, Ireland, to help distinguish its use from CXL for 
corneal ectasia and to avoid scientific confusion.19 However PACK-CXL is not routinely used 
in clinical practice due to the uncertainty of its efficacy and safety. This is primarily attributed 
to the wide heterogeneity of the literature in relation to the patient cohort, causative 
microorganisms, characteristics and severity of the ulcers, and treatment protocol, and the 
lack of large randomized control trials (RCTs). The aim of this quantitative systematic review 
is to examine the efficacy and safety of PACK-CXL based on the current literature.
METHODS
Protocol and registration
The systematic review title and protocol were registered with PROSPERO (registration 
number: CRD42019131290) and the Joanna Briggs Institute Database of Systematic 
Reviews and Implementation Reports.20
Data sources and search methods
Two authors (D.S.J.T and C.H.) searched MEDLINE (January 2003 to April 2019), EMBASE 
(January 2003 to April 2019), Cochrane Central Register of Controlled Trials (CENTRAL), 
ISRCTN registry (www.isrctn.com/editAdvancedSearch), US National Institutes of Health 
Ongoing Trials Register ClinicalTrials.gov (http://clinicaltrials.gov) and World Health 
Organization (WHO) International Clinical Trials Registry Platform (ICTRP) 
(www.who.int/ictrp) for primary research related to CXL for infectious keratitis or “PACK-
CXL”. The start date of January 2003 was selected because CXL was only introduced to 
clinical practice in 2003. There was no date restriction in the search for trials, however the 
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search was restricted to English articles. Electronic databases were first searched on 05 
August 2018, followed by a final update on 15 April 2019. Key words used were “cross-
linking”, “PACK-CXL”, “riboflavin”, “Vitamin B”, “keratitis”, “corneal ulcer”, and “corneal 
infection”. The bibliographies of included articles were independently and manually screened 
by two authors (D.S.J.T and C.H.) to identify further relevant studies. Search strategies for 
MEDLINE and EMBASE are provided in the Supplemental Table S1.
Study selection
All clinical studies, encompassing randomized controlled trials (RCTs), non-randomized 
controlled studies (NRS), case series and case reports, related to PACK-CXL were included 
as few RCTs were anticipated. The analysis was conducted at two levels; (1) a meta-
analysis of all eligible RCTs and (2) a systematic review of all clinical studies, including NRS, 
case series and case reports. All types of IK, including bacterial, fungal, viral, parasitic or 
mixed infection, were included in this review. Studies related to suspected non-infectious 
causes of keratitis or CXL used for non-antimicrobial purpose were excluded from this study. 
For the meta-analysis, the intervention group included cases of IK that were treated by 
PACK-CXL with standard antimicrobial therapy (SAT) whereas the control group included 
cases of IK that were treated with SAT alone. Restriction was made to publications in 
English but no restriction was applied to the location or setting of the study, or patients’ 
demographic factors. This study conformed to the Preferred Reporting Items for Systematic 
reviews and Meta-Analysis (PRISMA) guideline.
Data extraction
A web application designed for systematic reviews, Rayyan (Qatar), was used to help collate 
the potential studies and expedite the initial screening of abstracts and titles.21 The titles and 
abstracts obtained from the searches were independently screened by two authors (D.S.J.T 
and C.H.) to include studies that fulfilled the eligibility criteria. The authors then 
independently assessed the full-text version of all the selected articles and extracted data 
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onto a standardized data collection form for qualitative review. The extracted data included 
the authors and study title, year of publication, sample size, types of interventions, types of 
causative microorganisms, results and complications. Discrepancies were resolved by group 
consensus and independent adjudication (H.S.D) if consensus could not be reached.
For the meta-analysis, the following information were extracted from the included RCTs and 
entered into RevMan (Review Manager 5.3) software:
(1) Study characteristics: Year of publication, country of study, prospective registration of 
clinical trials in a publicly accessible database, sample size, eligibility criteria, 
demographic factors, diagnostic criteria, method of randomization, method of 
masking, number of study arms, number of participants, types of interventions, types 
of comparators, use of antimicrobial therapy in the intervention arm, source of 
funding, and any potential conflict of interest.
(2) Outcomes: Primary and secondary outcomes, risk of adverse events, complications 
during the procedure, post-procedure complications or secondary surgery, duration 
of follow-up, loss to follow-up and intervals at which outcomes were assessed.
Outcome measures
For the meta-analysis, the primary outcome measure was the time to complete corneal 
healing (defined as complete corneal re-epithelialization and clearance of infiltrate and 
hypopyon; days) and the secondary outcome measures included the size of epithelial defect 
(mm2) and size of infiltrate (mm2) at 7 days and at final follow-up (14 to 30 days), visual 
acuity (LogMAR) at final follow-up (one to three months), and risk of adverse events (defined 
as worsening IK and/or corneal melt or perforation requiring tectonic / therapeutic 
keratoplasty or evisceration) at final follow-up (one to three months). A summary of the 
available data of all included studies was also performed and reported.
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Continuous variables such as time to complete corneal healing, size of corneal epithelial 
defect and infiltrate, and corrected-distance-visual-acuity (CDVA) were presented as mean 
with standard deviation (SD). In studies that reported median and interquartile range, the 
means and SDs were estimated using formulas reported by Wan et al.22 and the Cochrane 
Handbook estimator.22 Dichotomous variable such as risk of adverse events was defined by 
the number of participants with adverse events. 
Assessment of risk of bias
Risk of bias was assessed by two authors (D.S.J.T and C.H) independently and any 
disagreement was adjudicated by H.S.D. Included RCTs were assessed for sources of 
systematic bias according to the guidelines in Chapter 8 of the Cochrane Handbook for 
Systematic Reviews of Interventions.23 The review authors were not masked to the authors 
of the studies during this assessment. A judgement of 'high', 'low', or 'unclear' risk of bias 
was made for the following domains: (1) selection; (2) performance; (3) detection; (4) 
attrition; and (5) selective outcome reporting biases. NRS were assessed for risk of bias 
using the ROBINS-I tool24 against seven domains; the worst judgement in any of the 
domains was used as the overall risk of bias.  
Measure of treatment effect
Dichotomous data were measured as risk ratios (RRs) with 95% confidence intervals (CI) 
and continuous data as mean differences (MDs) with 95% CI. The unit of analysis was the 
participant and there was no issue with the unit of analysis in the included RCTs. The review 
was conducted based on the available data from the trials. When data were unavailable but 
the level of missing data and reasons for missing data in each group were similar, data were 
analyzed even when intention-to-treat (ITT) analysis was not performed.
Assessment of heterogeneity
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The heterogeneity of the RCTs and NRS was checked by careful review of the full-text, 
assessment of forest plots and examination of the I2 value with its confidence interval. The 
overall characteristics of the studies, in particular the types of participants and types of 
interventions were examined to assess the extent to which the studies were similar enough 
to make pooling study results sensible. The results of forest plots were reviewed for 
consistency of the size and direction of effects. I2 values greater than 50% were considered 
indicative of substantial heterogeneity and meta-analysis could not be conducted due to 
inconsistency of effect estimates.23 It was anticipated that some degree of heterogeneity will 
always exist due to clinical and methodological differences of the studies; therefore a 
random-effects model was used for the meta-analysis. The Chi² p-value was also 
considered as this has a low power when the number of studies were few. A p-value of <0.1 
was considered statistically significant.23
Data synthesis and analysis
A meta‐analysis was undertaken when there were sufficient similarities in the reporting of 
outcome measures. A random‐effects model in RevMan 5.3 was used in view of the 
expected heterogeneity across different studies. The Mantel-Haenszel method was 
employed for analyzing the risk ratio of adverse events in view of the small expected number 
of events. If there was inconsistency between the results of individual studies such that a 
pooled result might not be a good summary of the individual trial results – for example, the 
effects were in different directions or I² >50% and P <0.1 – the data were not pooled but 
described in narrative format. Where there was statistical heterogeneity the data were 
pooled when all the effect estimates were in the same direction, such that a pooled estimate 
would seem to provide a good summary of the individual trial results. Sensitivity analysis 
was performed by assessing the impact of including studies at high risk of bias for an 
outcome in one or more key domains. This was conducted by omitting each study in turn to 
examine the influence of individual studies (with high risk of bias) on the overall pooled 
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estimate. A summary of findings is presented below including the assessment of the quality 
of the evidence for outcomes using the GRADE approach with GRADE Pro/GDT software.25 
All RCTs were started with a rating of ‘high-quality’ evidence and were downgraded by one 
level for serious concerns (or by two levels for very serious concerns) regarding the risk of 
bias, inconsistency, indirectness, imprecision or publication bias. The quality of evidence of 
studies was graded by two assessors (D.S.J.T and C.H.) independently and any 
disagreement was adjudicated by H.S.D. 
Assessment of adverse events
In addition to the meta-analysis, a comprehensive review of adverse events was conducted 
where both experimental and quasi-experimental study designs including RCTs, NRS, and 
analytical observational studies such as prospective and retrospective cohort studies and 
case-control studies were reviewed. Descriptive case series and case reports were also 
reviewed for rare or uncommon adverse events. The risk of adverse events was graphically 
represented on albatross plots generated by the module installed on STATA 15.1 statistical 
software.26 Pooled estimates of the risk of adverse events across comparative studies, 
including RCTs and NRS, were calculated. The risk of adverse events of PACK-CXL was 
summarized according to the type of IK. Studies were categorized as bacterial, fungal, 
acanthamoeba, viral, mixed or culture-negative presumed IK cohort. Mixed IK cohort 
referred to studies that included more than one group of causative microorganism.
RESULTS
Literature search and study characteristics
The electronic searches last conducted on 15 April 2019 retrieved a total of 754 titles and 
abstracts (see Figure 1 for the PRISMA flow chart). After removing 181 duplicates and 
including two additional records identified through other sources, the remaining 573 records 
were screened and 521 references that were not relevant to the scope of the review were 
excluded. A total of 52 full-text copies of papers were assessed for eligibility. After excluding 
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6 ineligible articles,27-32 46 studies were included in the systematic review. These included 
four RCTs,33-36 two NRS,37, 38 20 case series,39-58 and 20 case reports,59-78 examining the 
efficacy and safety of PACK-CXL in 435 participants (438 eyes) with IK, of which 311 eyes 
received PACK-CXL with SAT, 15 eyes received PACK-CXL alone, and 112 eyes received 
SAT alone. All studies included one eye per participant except for Chan et al. study40 and 
Cristian et al. study.41 Within the group that received PACK-CXL with/without SAT, the 
causative microorganisms included 152 (46.6%) bacteria, 89 (27.3%) fungi, 20 (6.1%) 
acanthamoeba, 4 (1.2%) viruses, 20 (6.1%) mixed, and 41 (12.6%) culture-negative 
presumed IK. The main characteristics of all RCTs and non-RCTs, including the authors’ 
name, year of publication, number of treated participants, treatment protocol used, types of 
causative microorganisms, severity of IK, main results, adverse events, and visual outcome 
(if available), are summarized in Supplemental Tables S2 and S3, respectively. Outcomes 
of RCTs are analyzed and summarized under the meta-analysis section. In addition, two 
ongoing RCTs were identified from the searches of clinical trial registries 
(https://clinicaltrials.gov/ct2/show/NCT02570321 and 
https://clinicaltrials.gov/ct2/show/NCT02717871).
Meta-analysis of eligible RCTs
Overall description
The study characteristics of all RCTs are summarized in Supplemental Table S2. The four 
RCTs included a total of 115 participants, with 58 participants receiving PACK-CXL plus 
SAT (intervention group) and 57 participants receiving SAT alone (control group). These 
consisted of four single-centered RCTs, which was conducted separately in Iran,33 
Thailand,34 Egypt,35 and India.36 Trials included participants aged between 15 and 84 years 
(mean age of 40 – 56 years), with slight male preponderance (59.1%). Two RCTs34, 36 were 
prospectively registered with the clinicaltrials.gov (NCT01831206 and NCT02328053).
Types of microbes and severity of IK
11
The RCTs were heterogeneous in terms of the types of infection. Bamdad et al.33 and 
Uddaraju et al.36 included bacterial keratitis alone and fungal keratitis alone, respectively, 
whereas Kasetsuwan et al.34 included both bacterial and fungal keratitis in their studies. Said 
et al.35 included bacterial, fungal, acanthamoeba and mixed infection. None of the studies 
included viral infection. The collective microbiological profiles included 53 (46.1%) bacteria, 
30 (26.1%) fungi, 3 (2.6%) acanthamoeba, 8 (7.0%) mixed bacteria/fungi, and 21 (18.3%) 
culture-negative presumed IK. The proportion of the types of organisms was similar between 
intervention and control arms in all RCTs, except for one RCT35 where there was a 
significantly higher proportion of mixed bacteria/fungi infection in the intervention arm (7, 
33.3%) compared to the control arm (1, 5.3%; p=0.027).
Treatment protocols and outcome measures
All four trials compared PACK-CXL plus SAT with SAT alone. Dresden CXL protocol, using 
an irradiance of 3 mW/cm2 for 30 mins (total fluence 5.4mJ/cm2), was employed in all 
intervention arms. After enrolment the participants were treated with PACK-CXL immediately 
on the first day of presentation in two studies,33, 34 within 48 hours in one study,35 and after 
two weeks of non-improvement with SAT in one study.36 The primary and secondary 
outcome measures used in these RCTs are summarized in Table 1. They included size of 
stromal infiltrate and epithelial defect at 7 days and final follow-up (14 to 30 days),33, 34 time 
to complete corneal healing or treatment duration (defined as complete re-epithelialization of 
the ulcer and disappearance of the infiltrate and hypopyon),33, 35 adverse events35,36 (defined 
by corneal perforation and/or endophthalmitis and/or increase in infiltrate size by ≥2mm), 
and visual-acuity.34-36 The follow-up duration was between four and six weeks post-
treatment, except for one study which the duration was not specified.35 The lack of similarity 
in outcome measures limited the possibility for combining all data from individual RCTs.
Risk of bias
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Risk of bias was for RCTs determined by using the “risk of bias” assessment tool. Sequence 
generation, allocation concealment, masking of participants, personnel and outcome 
assessors, incomplete outcome data, and selective outcome reporting were considered 
(Figure 2). Sequence generation was unclear in two of the studies33, 34 where simple 
randomization was performed but the method was not clearly stated, potentially increasing 
the risk of bias. No details of attempts to conceal allocation of intervention assignment were 
given in two trials.33, 35 Masking of participants was not possible but masking of assessors 
was possible in most studies. All trials had complete data except Uddaraju et al.36 which 
reported outcomes for 13 participants of the intended 31 participants with fungal keratitis, as 
the trial was terminated early due to the concern of corneal perforation rate in the PACK-
CXL group. Selective reporting was not considered to be a problem in the included trials but 
it was not always possible to assess this risk of bias adequately for one trial.35 Other 
potential risk of bias included the lack of prospective registration of clinical trial in a publicly 
accessible database in two studies33, 35 and the presence of conflict of interest in one study35 
where one of the lead authors was a co-inventor for the CXL technology (UV light source). 
Risk of bias for NRS was determined by using the ROBINS-I grading criteria. Two NRS 
identified from database search were graded as having critical risk of bias (score 4), as both 
studies showed selection bias of participants and lacked balance of unknown confounding 
factors.37, 38 Both studies had post-intervention bias in terms of the care provided and 
measurement of outcomes. One study had bias due to missing follow-up data.37 
Effects of interventions
The effects of interventions were categorized into: (A) time to complete corneal healing; (B) 
size of epithelial defect; (C) size of infiltrate; (D) corrected-distance-visual-acuity (CDVA) in 
LogMAR; and (E) risk of adverse events. The GRADE summary of findings for each 
treatment outcome is summarized in Table 2.
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A. Time to complete corneal healing 
Two RCTs reported the time to complete corneal healing (or treatment duration), which was 
defined as complete re-epithelialization and disappearance of infiltrate and hypopyon.33, 35 
There is very low-quality evidence that adjuvant PACK-CXL shortened the time to complete 
healing compared to SAT alone (MD -7.44 days; 95% CI -10.71 to -4.16; I2=0%; p<0.0001) 
(Figure 3A). Notably, the size of corneal ulcer in the adjuvant PACK-CXL group was 
significantly larger than the control group at baseline in one study.35 Quality of evidence was 
downgraded due risk of bias and imprecision. There was a lack of allocation concealment 
and blinding. The total number of participants pooled in the meta-analysis were less than the 
number generated by a conventional sample size calculation.
B. Size of epithelial defect
Two studies reported the size of epithelial defect at 7 days and final follow-up (14 to 30 
days).33, 34 There is very low-quality evidence that adjuvant PACK-CXL was equally effective 
as SAT alone in reducing the size of corneal epithelial defect at 7 days follow up (MD -3.66 
mm2; 95% CI -14.26 to 6.94; I2=50%; p=0.50) (Figure 3B). The quality of evidence was 
downgraded due to risk of bias, inconsistency and imprecision. In terms of the size of 
epithelial defect at final follow-up (14 to 30 days), there was heterogeneity between the two 
studies so meta-analysis was not performed (I2=58%). There is very low-quality evidence 
that adjuvant PACK-CXL was equally effective as SAT alone in reducing the size of corneal 
epithelial defect at final follow up. The quality of evidence was downgraded due to risk of 
bias, inconsistency, indirectness and imprecision. Final follow-up differed between 14 days 
and 30 days. The observed heterogeneity could be due to the mixed cohort of bacterial and 
fungal keratitis cases included in Kasetsuwan et al. study34 where 60% of the cases were 
fungal. When analysis of only bacteria keratitis cases was performed, the size of epithelial 
defect at final follow-up (14 to 30 days) favored PACK-CXL (MD -6.60; 95% CI -9.64 to -
3.57; p<0.0001).33, 34
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C. Size of infiltrate
Two studies reported the size of infiltrate at 7 days and final follow-up (14 to 30 days).33, 34 
There is very low-quality evidence that adjuvant PACK-CXL was more effective than SAT 
alone at reducing the size of infiltrate at 7 days’ (MD -5.49mm2; 95% CI -7.44 to -3.54; 
I2=0%; p<0.0001) and at final follow-up (MD -5.27mm2; 95% CI -9.12 to -1.41; I2=21%; 
p=0.007) (Figure 3C). The quality of the evidence was downgraded due to high risk of bias 
and imprecision. 
D. Visual acuity
There is very low-quality evidence that there was no difference in the mean CDVA at the 
final follow-up (one to three months) between the adjuvant PACK-CXL group and the SAT 
group (0.08; 95% CI -0.21 to 0.37; I2=9%; two RCTs with 70 participants)34, 35 (Figure 3D). 
The quality of the evidence was downgraded due to high risk of bias and imprecision. 
E. Adverse events
Adverse events were defined as worsening IK and/or corneal melt or perforation requiring 
tectonic / therapeutic keratoplasty or evisceration. Bamdad et al.33 reported no event of 
corneal perforation in both treatment arms though three participants required secondary 
surgeries such as amniotic membrane transplant (AMT) or conjunctival flap (one in PACK-
CXL group and two in standard care group). For the other three RCTs, a total of eight 
participants randomized to PACK-CXL required therapeutic keratoplasty or evisceration for 
uncontrolled IK compared to 11 participants that received SAT.34-36 There is very low-quality 
evidence that adjuvant PACK-CXL patients did not reduce the rate of adverse events at final 
follow-up (one to three months) when compared to SAT alone [risk ratio (RR) 0.84; 95% CI 
0.26 to 2.71; p=0.77; four studies with 115 participants]. A sensitivity analysis was performed 
with the exclusion of Uddaraju et al. study because early trial termination might bias the 
effect estimate.36 When excluded, there was no statistically significant change in the effect 
estimate on the risk of adverse events between adjuvant PACK-CXL and SAT alone (RR 
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0.49; 95% CI 0.11 to 2.29; I2=22%; p=0.37; three RCTs with 102 participants) (Figure 3E). 
The quality of evidence was downgraded due to high risk of bias and imprecision.  There are 
few events and the confidence interval included appreciable benefit and harm. Two studies 
did not report the type of microorganism involved in cases that were complicated by corneal 
perforation.34, 35 According to consort harms reporting guidance, we found the quality of 
harms reporting inadequate in three included studies where the severity of adverse events 
and clinical sequalae were not clearly described.34-36 
Subgroup analysis
There were insufficient RCTs to perform subgroup analysis between bacterial and fungal 
keratitis outcomes.  
As effectiveness RCTs are lacking, NRS were included in the assessment of time to 
complete healing and adverse events. The mean time to complete corneal healing and 
number of adverse events reported in all comparative interventional studies, including RCTs 
and NRS, are summarized in albatross plots (Figure 4). All comparative studies 
investigating time to complete healing favored adjuvant PACK-CXL,33, 35, 37, 38 with one study 
of bacterial keratitis showing statistical significance.33 In terms of the risk of adverse events, 
one study showed negative association favoring adjuvant PACK-CXL in mixed IK cohort and 
one study showed a positive association favoring SAT alone in fungal keratitis cohort; 
however none of the comparative studies showed statistical significance.34-38 Pooled risk 
estimates of adjuvant PACK-CXL on the risk of adverse events in comparative studies were 
grouped and analyzed according to type of IK cohorts (Table 3). It was found that adjuvant 
PACK-CXL did not significantly influence the risk of adverse events in mixed IK (RR 0.57; 
95% CI 0.20 to 1.61) and fungal keratitis cohorts (RR 1.30; 95% CI 0.66 to 2.54). 
Case series and case reports were reviewed for uncommon or unexpected adverse events. 
Analysis of the outcomes of the PACK-CXL, based on different types of causative 
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microorganisms, are summarized in Supplemental Table S4. Studies that reported pooled 
results with no distinction among the causative microorganisms were excluded from the 
subgroup analysis. Based on large NRS (≥ 5 eyes for a particular type of microorganism),38, 
39, 41, 42, 44, 46, 47, 49, 51-53, 55, 57, 58 the overall rate of complete corneal epithelial healing was 
84.8% (78/92) for bacterial keratitis, 73.5% (36/49) fungal keratitis, 66.7% (4/6) 
acanthamoeba keratitis, and 92.0% (23/25) culture-negative presumed IK. There was 
insufficient evidence on the use of PACK-CXL in acanthamoeba and mixed infection 
whereas viral keratitis was considered a contraindication for PACK-CXL in the majority of the 
studies. Based on small case series and case reports, the complete healing rate was 
reported to be 75% (9/12) for acanthamoeba keratitis, 33% (1/3) for mixed bacterial / fungal 
keratitis, 75% (3/4) for mixed acanthamoeba / fungal keratitis, 100% (1/1) for mixed bacterial 
/ acanthamoeba keratitis, and 25% (1/4) for viral keratitis.
Characteristics of ongoing studies
Two ongoing RCTs, comparing PACK-CXL and/or SAT with SAT alone, were identified from 
the searches of clinical trial registries. One RCT, named Cross-linking for Corneal Ulcers 
Treatment Trial (CLAIR), is recruiting 266 participants with bacterial or fungal keratitis 
(https://clinicaltrials.gov/ct2/show/NCT02570321). The primary outcome measure is the 
microbiological cure on repeat culture after adjuvant PACK-CXL or SAT alone. The other 
RCT, named Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis, is 
enrolling 252 participants with bacterial, fungal or mixed bacterial / fungal keratitis 
(https://clinicaltrials.gov/ct2/show/NCT02717871). This trial is investigating PACK-CXL as a 
primary treatment alone in early IK. The time to re-epithelialization of the cornea and time 




To the best of our knowledge, this study represents the most up-to-date and comprehensive 
systematic review and meta-analysis examining the effectiveness and safety of PACK-CXL 
in 435 participants (438 eyes), of which 325 participants received PACK-CXL with / without 
SAT. Since the last systematic review on PACK-CXL conducted by Abbouda et al.79 
(consisting of 21 studies of 145 eyes) and Papaioannou et al.80 (consisting of 25 studies of 
210 eyes) in 2016, a further 21 studies (including two additional RCTs) of 215 participants 
have been published. The doubling amount of literature on PACK-CXL in the recent years 
highlights a growing demand for innovative antimicrobial treatment for refractory IK, and the 
increasingly challenge faced by the clinicians in managing advanced and complex cases of 
IK. Both previous systematic reviews highlighted the potential utility of PACK-CXL but further 
high-quality RCTs were required.79, 80 However the conclusion was not based on the findings 
of meta-analysis, primarily due to the limited number of published RCTs during the conduct 
of the systematic reviews.
Summary of main findings
In this systematic review, we included four RCTs with 58 participants in the intervention 
group (PACK-CXL with SAT) and 57 participants in the control group (SAT alone). The 
majority of the studies focused on either bacterial or fungal keratitis or a combination of both, 
with only one RCT including acanthamoeba keratitis (three participants). None of the RCTs 
examined the utility of PACK-CXL in viral keratitis. Based on the meta-analysis of two RCTs 
with 72 participants, we demonstrated that adjuvant PACK-CXL shortened the time to 
complete corneal healing by 7 days when compared to SAT alone. One study33 included 
only participants with bacterial keratitis and the other study primarily included bacterial, 
fungal and mixed IK.35 In addition adjuvant PACK-CXL was superior to SAT alone in terms 
of the resolution of the size of infiltrate at 7 days and at final follow-up (14-30 days).33, 34 
These two RCTs examined a total of 62 participants with 44 culture-proven and presumed 
bacterial keratitis and 18 culture-proven and presumed fungal keratitis. Both studies included 
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primarily moderate IK (2-6 mm ulcer size and involved up to the anterior two third of the 
stroma) and severe IK (>6 mm ulcer size and involved the posterior one third of the stroma). 
In terms of other outcomes, adjuvant PACK-CXL did not reduce the risk of adverse events 
such as corneal perforation when compared to SAT alone group. While three RCTs showed 
a similar or lower risk of adverse events in the PACK-CXL group, Uddaraju et al.36 reported 
an opposite trend in their study. The latter study included cases of severe and refractory 
fungal keratitis that involved the posterior two third of the cornea and did not respond to the 
standard anti-fungal treatment for at least two weeks. Their findings might be confounded by 
the difference in the baseline severity of the fungal keratitis where the PACK-CXL group was 
considerably worse than the SAT group. Based on their findings, they have cautioned the 
use of PACK-CXL in patients with severe deep fungal infection. When Uddaraju et al. study 
was excluded from the analysis (due to early termination and significant difference in the 
baseline severity of the ulcer), there was an increase in direction favoring towards the use of 
adjuvant PACK-CXL in reducing the risk of adverse events (RR 0.49) but the difference was 
not statistically significant. There was also no significant difference between adjuvant PACK-
CXL and SAT alone for other outcomes such as the size of epithelial defect and corrected-
distance-visual-acuity (CDVA).
Based on NRS and case series (≥ 5 participants for a particular type of microorganism), we 
observed a complete healing rate of 84.8% (78/92) for bacterial keratitis, 73.5% (36/49) 
fungal keratitis, 66.7% (4/6) acanthamoeba keratitis, and 92.0% (23/25) culture-negative 
presumed IK. Only one participant (1.1%) in the bacterial keratitis group and three 
participants (6.1%) in the fungal keratitis group required additional AMT to help achieve 
complete re-epithelialization. These findings suggest that PACK-CXL may serve as a useful 
adjuvant therapy for bacterial and fungal keratitis. However, there were insufficient data to 
support the adjuvant use of PACK-CXL in acanthamoeba, mixed and viral IK. 
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Overall completeness and applicability of evidence
Overall the evidence was very low-quality with only four RCTs reporting small sample sizes. 
Price et al.52 and Hafezi and Kling19 had previously performed sample size power calculation 
for evaluating the effectiveness of PACK-CXL and had highlighted that around 200-250 
participants were required. However, the sample size in all four included RCTs was 
substantially underpowered in efficacy and safety outcomes. Small sample sizes precluded 
any subgroup analysis of different causative microorganisms. 
The other limiting issue with the meta-analysis was the inconsistency in measurement and 
reporting of the treatment outcomes among the four included RCTs. There was a total of 
eight different outcomes being reported and risk of adverse events was the only outcome 
that was consistently examined in all four RCTs. Two studies reported time to complete 
healing (defined by complete corneal re-epithelialization with clearance of infiltrate and 
hypopyon). Although this serves as a good outcome measure, it is important to bear in mind 
that some eyes with IK may develop delayed corneal epithelial wound healing or persistent 
epithelial defect after complete sterilization of the ulcer in relation to neurotrophic 
keratopathy. Interestingly a transient increase in hypopyon may be observed within 24 hours 
after PACK-CXL, likely attributed to the significant death of microorganisms and release of 
endotoxins, similar to a Jarisch-Herxheimer reaction.35 In addition, potential confounding 
factors such as age and status of diabetes may affect the corneal wound healing time.81-83 
Visual outcome was examined in three RCTs; however, this parameter is often not the best 
outcome measure for IK because it can be confounded by the location (e.g. whether the 
visual axis is affected) and the severity of the corneal ulcer, which may vary significantly 
between cases. 
Other important issue related to the evaluation of the efficacy of PACK-CXL was that some 
studies included deep corneal ulcers/infiltrates which were outside the Dresden protocol 
therapeutic window of 400 µm of the cornea. Spoerl et al.84 reported that 94% of the UVA 
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was absorbed in the anterior 400 µm of the cornea, therefore deeper ulcers are unlikely to 
benefit from adjuvant PACK-CXL. In addition, some studies included eyes with corneal 
thickness of <400 µm, which could potentially increase the risk of endothelial dysfunction 
following PACK-CXL.85 Anterior segment optical coherence tomography would better 
quantify the depth of ulcer and the corneal thickness than slit lamp examination or 
ultrasound pachymetry for eyes with IK as these two parameters can be highly variable. It is 
also noteworthy to mention that the 400 µm limit is based on CXL studies on healthy 
corneas but not on inflamed or infected corneas. It is likely that the transmission of UV light 
behaves differently in infected corneas59 but further research studies are required to 
elucidate this aspect. Corneal densitometry using Pentacam Scheimpflug imaging system 
may also serve as a useful adjuvant tool for monitoring the corneal response to IK.86 Many 
studies reported the application of fluorescein stain prior to PACK-CXL to measure the size 
of the epithelial defect. This has an important clinical implication because the presence of 
fluorescein could compete with riboflavin for energy at 365 nm and reduce the effectiveness 
of PACK-CXL.87 However, it is not always possible to ascertain the interval between the 
application of fluorescein drop and the initiation of PACK-CXL. 
Based on the available evidence, three RCTs demonstrated that adjuvant PACK-CXL could 
expedite the resolution of IK in bacterial keratitis and potentially fungal keratitis, in terms of 
size of infiltrates33, 34 and time taken to complete healing.35 In contrast there were insufficient 
data to perform any meaningful analysis for acanthamoeba, viral and mixed IK. Several in 
vitro studies have shown that PACK-CXL did not confer any positive anti-amoebic effect on 
acanthamoeba cyst or trophozoites.88, 89 Interestingly, when riboflavin was substituted with 
rose bengal, PACK-CXL was shown to demonstrate effective anti-amoebic activity.88 Based 
on histopathologic examination, Hager et al.28 similarly reported the persistence of 
acanthamoeba cyst and trophozoites in the acanthamoeba-infected corneal buttons after 
combined PACK-CXL and cryotherapy. PACK-CXL should not be employed to treat viral 
keratitis as UV radiation may exacerbate or activate herpes simplex infection.52, 90
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Quality of evidence and potential biases in the review
All four RCTs were associated with a high risk of performance bias (the participants and 
investigators were not masked from the procedure) and at least one or more high / unclear 
risk of bias in other domains. The overall quality of the evidence was judged to be very low 
(see Table 2). As such, further research is very likely to have an important impact on the 
confidence in the estimate of effect and is likely to change the estimate. The main reasons 
for downgrading the evidence included risk of bias in the included studies, inconsistency, 
imprecision and indirectness. Other important risk of bias included the lack of prospective 
registration of the clinical trial in a publicly accessible database33, 35 and the presence of 
conflict of interest.35 As fewer than 10 studies were eligible for inclusion, we were unable to 
use a funnel plot to identify possible publication bias. Due to the potential bias, D.G.S. (who 
is the first author in Said et al. study)35 was not involved in the data analysis of this 
systematic review. 
In summary, adjuvant PACK-CXL may serve as a useful addition to the therapeutic 
armamentarium for IK in reducing the time to complete healing and size of infiltrate. There 
remains uncertainty regarding the effectiveness and safety of adjuvant PACK-CXL in the 
treatment of fungal keratitis and its use was cautioned in severe deep fungal cases. The use 
of PACK-CXL in acanthamoeba keratitis remains elusive, with contradicting evidence from in 
vitro and clinical studies, whereas PACK-CXL is contraindicated in cases of viral keratitis. 
Further adequately powered, high-quality RCTs are required to provide a true evaluation of 
the effectiveness and safety of PACK-CXL. Standardization of the reporting of outcome 
measures will enable better applicability of the evidence and allow easier comparison of the 
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Figure 1. PRISMA flow diagram of the literature search for “Photoactivated chromophore for 
infectious keratitis – corneal cross-linking (PACK-CXL).
Figure 2. Risk of bias graph: Review authors' judgements about each risk of bias item 
presented as percentages across all included studies.
Figure 3. Summary of the meta-analysis (forest plot) comparing the efficacy between PACK-
CXL plus standard antimicrobial treatment (SAT) and SAT alone in eligible randomized 
controlled trials, in terms of: (A) time to complete corneal healing; (B) size of epithelial 
defect; (C) size of stromal infiltrate; (D) corrected-distance-visual-acuity; and (E) risk of 
adverse events.
Figure 4. (A) Albatross plot for studies comparing the mean time to healing of adjuvant 
PACK-CXL with standard antimicrobial treatment (SAT) alone, with contours for mean 
differences (MDs). Red points represent comparative studies of fungal keratitis, black points 
represent mixed infectious keratitis cohorts, and green point represents study that included 
bacterial keratitis. Negative association favors the use of adjuvant PACK-CXL and positive 
association favors the use of SAT alone. Points lying outside the p-value of 0.05 were 
considered statistically significant. (B) Albatross plot for studies comparing adverse events 
of adjuvant PACK-CXL with SAT alone for infectious keratitis with contours for relative risk 
(RR). Red points represent comparative studies of fungal keratitis and black points represent 
mixed infectious keratitis cohorts. Negative association favors the use of adjuvant PACK-
CXL and positive association favors the use of SAT alone. Points lying outside the p-value of 





Table 1. Primary and secondary outcome measures used in randomized controlled trials 
evaluating the effect of photoactivated chromophore for infectious keratitis – corneal cross-
linking (PACK-CXL).
Authors (year) Primary Outcome Measures Secondary Outcome Measures
Kasetsuwan et al. (2016) (1) Size of stromal infiltrate (1) Size of epithelial defect
(2) Treatment failure
(3) BPVA
Uddaraju et al. (2015) (1) Treatment failure at 6 weeks (1) UDVA
Bamdad et al. (2015) Not specified but following parameters were analyzed and reported: 
(1) Size of epithelial defect
(2) Size of stromal infiltrate
(3) Grade of corneal ulcer
(4) Duration of treatment
(5) Treatment failure
Said et al. (2014) Not specified but following parameters were analyzed and reported: 
(1) Time to complete healing (defined by complete corneal 
epithelialization and clearance of infiltrate)
(2) CDVA
(3) Treatment failure
BPVA = Best-corrected-pinhole-visual-acuity; UDVA = Uncorrected distance visual acuity; 
CDVA = Corrected distance visual acuity
PACK-CXL compared to standard antimicrobial treatment for Infectious Keratitis
Patient or population: Infectious Keratitis 
Intervention: PACK-CXL 











(95% CI) Risk with standard 
antimicrobial treatment
Risk difference with PACK-
CXL*
Mean time to healing 72(2 RCTs) 
⨁◯◯◯
VERY LOW a,b - 24.7 to 46.1 days 
MD 7.44 days shorter
(10.71 shorter to 4.16 shorter) 





VERY LOW a,b - 14.94 to 20.9 mm
2 MD 3.66 mm
2 smaller
(14.26 smaller to 6.94 smaller) 
Size of epithelial defect at final 




VERY LOW a,b,c,d - 4.9 to 8.31 mm
2 MD 5.09 mm
2 smaller






VERY LOW a,b - 14.88 to 28.1 mm
2 MD 5.49 mm
2 smaller
(7.44 smaller to 3.54 smaller) 
Size of infiltrate at final follow-




VERY LOW a,b,d - 9.3 to 9.63 mm
2 MD 5.27 mm
2 smaller
(9.12 smaller to 1.41 smaller) 
CDVA (LogMAR) at final follow-




VERY LOW a,b,d - 1.2 to 1.67
MD 0.08 LogMar worse
(0.21 better to 0.37 worse) 
Adverse events at final follow-






(0.11 to 2.29) 140 per 1,000 
71 fewer per 1,000
(125 fewer to 181 more) 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect 
of the intervention (and its 95% CI). 
CI: Confidence interval; MD: Mean difference; RR: Risk ratio 
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate 
of effect 
Explanations
a. High risk of bias due to lack of allocation concealment and blinding. 
b. Total number of participants is less than the number generated by a conventional sample size calculation. 
c. There is significant heterogeneity. 
d. Differences in final follow-up 
e. There are few events and the confidence interval includes appreciable benefit and harm. 
Table 3. Pooled risk estimates of PACK-CXL on risk of adverse events in comparative studies 
grouped and analyzed according to type of infectious keratitis (IK) cohorts. 
IK cohorts Number of 
Studies
Types of studies Number of 
participants
Estimate of magnitude 
(95% CI)
Bacterial 1 1 RCT23 32 NK
Mixed* 4 2 RCTs24,25
1 NRS27
115 RR 0.57 (0.20 to 1.61)
Fungal 2 1 RCT26
1NRS28
54 RR 1.30 (0.66 to 2.54)
RCT = Randomized controlled trial; NRS = Non-randomized controlled studies; CI = Confidence 
interval; RR = Risk ratio; NK = Not known
*Mixed IK cohorts refer to cohorts consisting of two or more types of IK, which could be either 
bacterial, fungal, acanthamoeba or mixed IK.













13. Exp Corneal Ulcer/
14. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
15. 9 or 10 or 11 or 12 or 13
16. 14 and 15
17. Limit 16 to humans
18. Limit 17 to yr=”2003 – 2019’













13. Exp corneal ulcer/
14. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
15. 9 or 10 or 11 or 12 or 13
16. 14 and 15
17. Limit 16 to humans
18. Limit 17 to yr=”2003 – 2019”
Table S2. Summary of all randomized control trials evaluating the effectiveness and safety of photoactivated chromophore for infectious 
keratitis-corneal cross-linking (PACK-CXL).
Causative organisms (in CXL group)Authors Year Protocol 
registration*





(control) B F A V M CN
Bamdad et al. 2015 N Mean = 39.6 (CXL) 
vs. 40.3 (control)
21 (66%) 16 16 16
Kasetsuwan et al. 2016 Y Mean = 45 (CXL) 
vs. 54 (control)
21 (70%) 15 15 7 8
Said et al. 2014 N Mean = 37 (CXL) 
vs. 50 (control)
18 (45%) 21 19 7 3 1 0 7 3
Uddaraju et al. 2015 Y Median = 40 (CXL) 
vs. 56 (control)













Severity of ulcer$ Follow-up COI
Bamdad et al. - Same day 3mW/cm2 for 
30mins
Y Mean = 17mm2 (CXL) vs. 
20mm2 (control)
1 month N
Kasetsuwan et al. Mean = 1.8 (CXL) 
vs. 1.7 (control)
Same day 3mW/cm2 for 
30mins
Y Median = 31mm2 (CXL) vs. 
31mm2 (control)
1 month N






Y Mean = 30mm2 (CXL) vs. 
16mm2)
2 weeks – 
4 months
Y
Uddaraju et al. Median = HM (CXL) 
vs. HM (control)
After 2 weeks 3mW/cm2 for 
30mins
Y Deep stromal; median = 7mm 
(CXL) vs. 5mm (control)
- N
*Prospective registration of the clinical trial protocol in a publicly accessible database. 
B = Bacteria; F = Fungi; A = Acanthamoeba; V = Viruses; M = Mixed infection; CN = Culture-negative presumed infectious keratitis; SAT = Standard 
antimicrobial treatment; COI = Conflict of interest; IQR = Interquartile range; HM = Hand movement
Table S3. Summary of all clinical studies (excluding randomized control trials) evaluating the effectiveness and safety of photoactivated 
chromophore for infectious keratitis-corneal cross-linking (PACK-CXL).





(control) B F A V M CN
Severity of ulcer$
Basaiawmoit et al. 2018 CCT 13* 32 4 9 Mean = 15mm2 (CXL) 
vs. 13mm2 (control)
Vajpayee et al. 2015 CCT 20 21 20 Mean = 16mm2 (CXL) 
vs. 17mm2 (control)
Agrawal et al. 2016 Case series 6 - 1 5 4-9mm
Chan et al. 2014 Case series 4 2 2 1 1 11-64mm2














Iseli et al. 2008 Case series 5 - 3 2 -
Khalili et al. 2017 Case series 8 - 6 2 Severe (>6mm and 
involved posterior 1/3)
Khan et al. 2011 Case series 3 - 3 3-6mm
Knyazer et al. 2018 Case series 20 - 9 1 1 9 2-7mm and <300µm 
depth
Li et al. 2013 Case series 8 - 8 1-6mm
Makdoumi et al. 2012 Case series 16 - 12 4 Median = 1mm
Makdoumi et al. 2010 Case series 7 - 4 3 0.25mm2 – total cornea
Muller et al. 2012 Case series 6 - 3 2 1 -
Panda et al. 2012 Case series 7 - 1 1 5 Grade 3-5
Price et al. 2012 Case series 40 - 24 7 2 1 6 0.3-104mm2
Ramona et al. 2016 Case series 10 - 10 -
Rosetta et al. 2013 Case series 4 - 3 1 Severe ulcer +/- melt
Shetty et al. 2014 Case series 15 - 9 6 Mild (superficial) to 
severe (full-thickness)
Skaat et al. 2014 Case series 6 - 3 3 2-5mm 
Sorkhabi et al. 2013 Case series 10 - 9 1 12mm2 – total cornea
Zloto et al. 2018 Case series 18 - 13 5 Mean = 10mm2
Abbouda et al. 2014 Case report 2 - 2 >6mm
Anwar et al. 2011 Case report 2 - 1 1 4-6mm
Arance-Gil et al. 2014 Case report 1 - 1 -
Casagrande et al. 2014 Case report 1 - 1 Severe ulcer with 
thinning
Chan et al. 2017 Case report 1 - 1 1.5mm
Demirci et al. 2013 Case report 1 - 1 Ring ulcer with melt
Ferrari et al. 2013 Case report 1 - 1 -
Ferrari et al. 2009 Case report 1 - 1 -
Garduno-Vieyra et al. 2011 Case report 1 - 1 8mm, anterior stroma
Igal et al. 2017 Case report 1 - 1 3mm
Kozobolis et al. 2010 Case report 2 - 1 -
Kymionis et al. 2016 Case report 1 - 1 Severe deep infiltrate 
with perineuritis
Labiris et al. 2014 Case report 1 - 1 3.5 mm with severe 
thinning
Moren et al. 2010 Case report 1 - 1 -
Oflaz et al. 2017 Case report 1 - 1 20mm2
Passilongo et al. 2018 Case report 1 - 1 Deep stromal
Saglk et al. 2013 Case report 1 - 1 Deep stromal
Tabibian et al. 2014 Case report 1 - 1 1mm, anterior third of 
the stroma
Yagci et al. 2016 Case report 1 - 1 6mm2
Zarei-Ghanavati et al. 2015 Case report 1 - 1 -
$Severity of the corneal ulcer is presented either in maximum linear diameter (mm) or in area (mm2).
*Two patients lost to follow-up.
Table S3 (Continue). Summary of all clinical studies (excluding randomized control trials) evaluating the effectiveness and safety of 












Outcomes (i.e. healing time 









- Within 48 
hours
3mW/cm2 for 30mins Y Mean healing time = 22 days 
(CXL) vs. 49 days (control)
1 (CXL) vs. 
4 (control) 
- -
Vajpayee et al.  1.4 (CXL) 
vs. 1.5 
(control)
Same day 3mW/cm2 for 30mins Y Complete healing = 98% 
(CXL) and 86% (control); 
Mean healing time = 31 days 
(CXL) and 31 days (control); 
Corneal perforation in 2. 
(CXL) and 3 (control)
2 (CXL) vs. 
3 (control)
Mean = 1.1 
(CXL) vs. 1.3 
(control)
3 months
Agrawal et al. CF – PL >10 days 3mW/cm2 for 30mins Y Completely healing = 4 (67%) 2 (33%) HM – PL 3 months
Chan et al. Mean = 2.30 
(CXL) vs. 3.0 
(control)
Median = 6.5 
days
3mW/cm2 for 30mins Y Resolution of infiltrate in all 6 
cases; Complete ED healing 
= 2 (CXL) vs. 1 (control) 









Mean = 57 
days
Mean = 8 days
4.5mW/cm2 for 





Complete healing = 4 (67%); 
Mean healing time=109 days
7 (54%) healed completely, 6 
worsened; pain score 
improved from mean of 8 to 
3.5 (Those that improved 
were mainly mild-moderate 


















Khalili et al. 20/200 – PL Mean = 15 
days
3mW/cm2 for 30mins Y 67% bacterial keratitis 
healed; 50% viral keratitis 
healed
2 (25%) - -
Khan et al. - 1-2 months 3mW/cm2 for 30mins 
(x2)
Y Mean healing time = 5.3 
weeks
None - 4-12 
months
Knyazer et al. - 3 days 30mW/cm2 for 3mins Y Mean healing time = 6.5 days 1 (5%) - -









Same day 3mW/cm2 for 30mins N (2 needed 
SAT due to 
progression)
Complete healing = All 
(100%) cases (1 needed 
AMT);
Mean healing time = 7 days
None Median = 0.0 1-14 days
Makdoumi et 
al.
0.05 - PL 0-7 days 3mW/cm2 for 30mins Y Complete healing = All 
(100%) cases
None 0.08 – PL 1-6 
months
Muller et al. Mean = 1.3 Median = 3 
days
3mW/cm2 for 30mins Y Complete healing = 4 (67%) 
cases
1 (17%) Mean = 1.0 2-9 
months
Panda et al. - 30 – 120 days 3mW/cm2 for 30mins Y Complete healing = All 
(100%) cases; 
Mean healing time = 8.6 days
None - -
Price et al. - 0-45 days 
(90% within 10 
days)
3mW/cm2 for 15-
45mins (x2 in 7 
eyes)
Y Complete healing = 25 
(62.5%); Healing rate 
corresponds well with the size 
of infiltrate
7 (18%) - -
Ramona et al. - 14 days or 
longer
3mW/cm2 for 30mins Y Complete healing = 8 (80%) None Visual 
improved in 8 
eyes
12 months
Rosetta et al. - Mean = 6 days 3mW/cm2 for 30mins Y Mean ED healing time = 7.0 
days (bacteria); 10 days 
(acanthamoeba)
None Mean = 0.4 Mean = 
3.5 
months
Shetty et al. - 14 days or 
longer
3mW/cm2 for 30mins Y Complete healing = 9 (67%); 
Mean ED healing time = 21.3 
days, Mean infiltrate 
resolution time = 33.4 days. 
Improvement in pain score. 
3 (20%) - -
Skaat et al. Mean = 0.7 Mean = 12 
days
3mW/cm2 for 30mins Y Complete healing = 5 (83%); 
Mean healing time = 17.2 
days
1 (17%) Mean = 0.22 Mean = 
1.5 
months
Sorkhabi et al. Mean = 1.9 - 3mW/cm2 for 30mins Y Complete healing = 8 (80%) 2 (20%) Mean = 1.5 -
Zloto et al. Mean = 1.5 Mean = 10 
days
9mW/cm2 for 10mins Y Not specified 1 (6%) CDVA 
maintained
-
Abbouda et al. - - 3mW/cm2 for 30mins Y Complete healing = 0% but 
melting was stopped in one 
case
1 (50%) - -
Anwar et al. CF – HM 21 days 3mW/cm2 for 30mins Y Completely healed in 2 cases 
(at 2 weeks – 2 months) 




- 1 year 3mW/cm2 for 30mins Y Infection not controlled and 
cornea melted 8 months post-
CXL requiring TK
1 (100%) 20/60 -
Casagrande et 
al.
PL - 3mW/cm2 for 30mins Y Complete healing at 2 months 
(had AMT at 1 month)
None 20/400 2 months
Chan et al. 20/50 2 days 18mW/cm2 for 5mins Y Complete healing in 2 weeks None 20/20 2 weeks
Demirci et al. - >2 months 3mW/cm2 for 30mins Y Complete healing at 10 days None - 2 months
Ferrari et al. - 12 days -
Ferrari et al. - - - - Complete healing at 30 days None - 1 month
Garduno-
Vieyra et al.
20/400 ~60 days 3mW/cm2 for 30mins Y Complete healing at 21 days None 20/20 5 months
Igal et al. - Not specified Y Complete healing None 20/80 2 years
Kozobolis et al. 20/400 – PL 3mW/cm2 for 30mins Y Complete healing in all cases 
at 7 days.
None 20/100 2 months
Kymionis et al. HM 3 months 3mW/cm2 for 30mins Y Complete healing at 2 months None - 2 months
Labiris et al. HM 3 days 3mW/cm2 for 30mins Y Complete healing at 5 days None - 12 months
Moren et al. 1.8 29 days 3mW/cm2 for 30mins Y Complete healing at 32 days None 0.2 9 months
Oflaz et al. HM 30 days 3mW/cm2 for 30mins Y Complete healing at 30 days None 20/400 6 weeks
Passilongo et 
al.
- ~40 days 9mW/cm2 for 9mins Y Perforation at 3 days post-
CXL
1 (100%) 20/40 16 months
Saglk et al. - 17 days 3mW/cm2 for 30mins 
(x2)
Y Complete healing at 7 days 
(post-2nd CXL)
None CF 6 months
Tabibian et al. 20/25 Same day 9mW/cm2 for 10mins N Complete healing at 3 days None 0.0 1 month
Yagci et al. - - 3mW/cm2 for 30mins Y No improvement post-CXL 1 (100%) 0.2 14 months
Zarei-
Ghanavati et al.
- 60 days 3mW/cm2 for 30mins Y Complete healing at 2 weeks None - 3 months
*Treatment failure was defined as uncontrolled / worsening infectious keratitis requiring tectonic keratoplasty or evisceration.
SAT = Standard antimicrobial treatment; CF = Counting fingers; HM = Hand movement; PL = Perception of light; NPL = No perception of light; ED = Epithelial 
defect; CDVA = Corrected-distance-visual-acuity
Table S4. Summary of the healing rate and treatment failure of PACK-CXL in non-
randomized controlled studies (NRS), case series and case reports based on the types of 
causative microorganisms. 









Agrawal et al. 2016 1 1 (100%) - 0 (0%)
Anwar et al. 2011 1 1 (100%) 14 0 (0%)
Casagrande et al. 2014 1 1 (100%) AMT 60 0 (0%)
Chan et al. 2014 2 1 (50%) 90 0 (0%)
Chan et al. 2017 1 1 (100%) 14 0 (0%)
Ferrari et al. 2009 1 1 (100%) 30 0 (0%)
Iseli et al. 2008 3 3 (100%) 28 – 120 0 (0%)
Khalili et al. 2017 6 4 (67%) - 2 (33%)
Knyazer et al. 2018 9 9 (100%) 4 – 30 0 (0%)
Kozobolis et al. 2010 1 1 (100%) 7 0 (0%)
Labiris et al. 2014 1 1 (100%) 5 0 (0%)
Makdoumi et al. 2012 12 12 (100%) 1 AMT 1 – 14 0 (0%)
Makdoumi et al. 2010 4 4 (100%) - 0 (0%)
Muller et al. 2012 3 2 (67%) 120 1 (33%)
Oflaz et al. 2017 1 1 (100%) 30 0 (0%)
Price et al. 2012 24 20 (83%) 4 – 40 3 (17%)*
Ramona et al. 2016 10 8 (80%) 30 2 (20%)
Rosetta et al. 2013 3 3 (100%) 3 – 45 0 (0%)
Shetty et al. 2014 9 6 (67%) 14 – 28 3 (33%)
Skaat et al. 2014 3 2 (67%) - 1 (33%)
Sorkhabi et al. 2013 9 7 (78%) - 2 (22%)
Zloto et al. 2018 13 12 (92%) - 1 (8%)
Fungal keratitis
Abbouda et al. 2014 2 0 (0%) - 1 (50%)
Anwar et al. 2011 1 1 (100%) 60 0 (0%)
Erdem et al. 2018 9 4 (44%) 3 AMT 15 – 33 4 (44%)
Igal et al. 2017 1 1 (100%) - 0 (0%)
Iseli et al. 2008 2 1 (50%) - 1 (50%)
Knyazer et al. 2018 1 1 (100%) 16 0 (0%)
Li et al. 2013 8 8 (100%) 3 – 8 0 (0%)
Muller et al. 2012 2 1 (50%) 120 1 (50%)
Price et al. 2012 6 3 (50%) 26 – 28 3 (50%)
Saglk et al. 2013 1 1 (100%) 7 (after 2nd 
CXL)
0 (0%)
Shetty et al. 2014 6 3 (50%) 15 – 90 3 (50%)
Sorkhabi et al. 2013 1 1 (100%) - 0 (0%)
Tabibian et al. 2014 1 1 (100%) 3 0 (0%)
Vajpayee et al. 2015 20 18 (90%) 15 – 90 2 (10%)
Yagci et al. 2016 1 0 (0%) - 0 (0%)
Acanthamoeba keratitis
Arance-Gil et al. 2014 1 0 (0%) - 1 (100%)
Chan et al. 2014 1 1 (100%) 60 0 (0%)














2011 1 1 (100%) 21 0 (0%)
Khan et al. 2011 3 3 (100%) 21 – 42 0 (0%)
Moren et al. 2010 1 1 (100%) 31 0 (0%)
Muller et al. 2012 1 1 (100%) - 0 (0%)
Price et al. 2012 2 0 (0%) 54 – 145
Rosetta et al. 2013 1 1 (100%) 10 0 (0%) 
Viral keratitis
Ferrari et al. 2013 1 0 (0%) - 1  (100%)
Khalili et al. 2017 2 1 (50%) 25 1 (50%)
Price et al. 2012 1 0 (0%) SK - 0 (0%)
Mixed bacterial / fungal keratitis
Erdem et al. 2018 2 1 (50%) 1 AMT - 1 (50%)
Knyazer et al. 2018 1 0 (0%) - 1 (100%)
Mixed acanthamoeba / fungal keratitis
Erdem et al. 2018 2 2 (100%) 15 – 35 0 (0%)
Kymionis et al. 2016 1 1 (100%) 60 0 (0%)
Passilongo et al. 2018 1 0 (0%) - 1 (100%)
Mixed acanthamoeba / bacterial keratitis
Panda et al. 2012 1 1 (100%) 8 0 (0%)
Culture negative
Agrawal et al. 2016 5 3 (60%) - 2 (40%)
Chan et al. 2014 1 1 (100%) 120 0 (0%)
Knyazer et al. 2018 9 9 (100%) - 0 (0%)
Kozobolis et al. 2010 1 1 (100%) 7 0 (0%)
Makdoumi et al. 2012 4 4 (100%) 4 – 12 0 (0%)
Makdoumi et al. 2010 3 3 (100%) - 0 (0%)
Panda et al. 2012 6 6 (100%) 5 – 18 0 (0%)
Skaat et al. 2014 3 3 (100%) 19 – 47 0 (0%)
Zarei-Ghanavati 
et al.
2015 1 1 (100%) 14 0 (0%)
Zloto et al. 2018 5 5 (100%) - 0 (0%)
*One patient lost to follow-up.
PACK-CXL = Photoactivated chromophore for infectious keratitis-corneal collagen cross-
linking; AMT = Amniotic membrane transplant
